

# JP-2266: Novel SGLT1/2 dual inhibitor for the treatment of diabetes mellitus

JEIL Pharmaceutical



METABOLIC	Phase 1
Product Type	Small Molecule
Indication	<ol style="list-style-type: none"> <li>1. Type 2 diabetes mellitus to improve glycemic control</li> <li>2. Type 1 diabetes mellitus, who have failed to achieve adequate glycemic control despite optimal insulin therapy</li> </ol>
Target	Sodium-glucose co-transporter-1 and 2 (SGLT1/2)
MoA(Mechanism of Action)	<ol style="list-style-type: none"> <li>1. Inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors)</li> <li>2. Also, inhibits Intestinal SGLT-1, delaying glucose absorption and therefore reducing postprandial glucose.</li> </ol>
Competitiveness	<ol style="list-style-type: none"> <li>1. Significant postprandial glucose &amp; HbA1c reduction in animal model</li> <li>2. Postprandial blood glucose lowering effect similar to a fast acting insulin</li> <li>3. Shows best postprandial glucose lowering effect amongst all SGLT inhibitors</li> </ol>
Development Stage	Phase 1
Route of Administration	Oral